Market capitalization | CHF17.86b |
Enterprise Value | CHF21.23b |
P/B ratio (TTM) P/B ratio | 2.33 |
Dividend yield | 1.11% |
Last dividend (FY23) | CHF0.45 |
P/E forward | 30.69 |
P/S forward | 1.97 |
EV/Sales forward | 2.34 |
As a Free StocksGuide user, you can view scores for all 6,883 stocks worldwide.
18 Analysts have issued a Sandoz forecast:
18 Analysts have issued a Sandoz forecast:
Mar '24 |
+/-
%
|
||
Revenue | 2,179 2,179 |
-
|
|
Gross Profit | - - |
-
|
|
EBITDA | - - |
-
|
EBIT (Operating Income) EBIT | - - |
-
|
Net Profit | - - |
-
|
In millions CHF.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Sandoz Group AG engages in focusing on generic pharmaceuticals and bio similar medical products. It acquires, manages and sells investments and intellectual property in the healthcare and medical device industry and conducts all business at home and abroad. The firm can acquire, sell, debit and manage interests in other companies, intellectual property rights and real estate at home and abroad, as well as establish branches and subsidiaries at home and abroad. The company was founded on January 17, 2022 and is headquartered in Rotkreuz, Switzerland.
Head office | Switzerland |
CEO | Richard Saynor |
Employees | 20,000 |
Founded | 2022 |
Website | www.sandoz.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.